MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is deploying artificial intelligence to transform drug and alcohol testing with a non-invasive voice analysis technology. The company's platform analyzes more than 140 acoustic markers and is trained on over 50 million data points to estimate intoxication levels from short voice samples, offering an alternative to traditional breath, saliva, or laboratory testing.
The global alcohol and drug testing devices market is projected to grow from $2.5 billion in 2025 to $4.2 billion by 2033, driven by rising safety requirements and stricter regulatory oversight. This growth creates opportunities for companies like MindBio to modernize a process that remains heavily dependent on breathalyzers, urine testing, and laboratory analysis.
Mining is MindBio's initial commercial focus, particularly in South America, where large workforces and high-risk operating environments create demand for rapid impairment screening. Other potential applications include aviation, construction, call centers, law enforcement, and mental health settings where high-volume screening is currently expensive and time-consuming.
The technology is designed for both workplace and non-workplace settings. Employers face increasing pressure to improve safety while reducing the cost and friction of traditional testing methods. MindBio's approach uses artificial intelligence to analyze voice samples, potentially enabling rapid, non-invasive testing that can be deployed at scale.
MindBio Therapeutics is a biotechnology company that has spent several years researching and developing this technology. The company is positioning itself in the expanding market for workplace drug and alcohol detection, where traditional methods are often invasive and logistically challenging.
For more information on MindBio Therapeutics Corp., visit the company's newsroom at https://ibn.fm/MBQIF.
